Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2− metastatic breast cancer

References

• Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:809–815.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–128.
   PubMed Web of Science ®Google Scholar
• Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:1.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2011 [Internet]. Bethesda (MD): National Cancer Institute; 2014 [cited 2018 Dec 8]. Available from: http://seer.cancer.gov‌/csr‌/1975_2011/
   Google Scholar
• Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–1785.
   PubMed Web of Science ®Google Scholar
• Noone AM, Howlader N, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2015 [Internet]. Bethesda (MD): National Cancer Institute. Based on November 2017 SEER data submission, posted to the SEER web site, 2018 April [cited 2018 Dec 8]. Available from: https://seer.cancer.gov/csr/1975_2015/
   Google Scholar
• Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7:304–320.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Hao Y, Meyer N, Song X, et al. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics. Curr Med Res Opin. 2015;31:275–288.
   PubMed Web of Science ®Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin. 2014;30:1537–1545.
   PubMed Web of Science ®Google Scholar
• Meyer N, Hao Y, Song X, et al. Healthcare resource use and expenditures among metastatic breast cancer patients treated with HER2-targeted agents. Int J Breast Cancer. 2014;2014:1.
   Google Scholar
• Muss HB. Coming of age: breast cancer in seniors. Oncologist. 2010;15(Suppl 5):57–65.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;2121:1383–1389.
   Web of Science ®Google Scholar
• Lang K, Huang H, Sasane M, et al. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER–Medicare data. BMC Health Serv Res. 2014;14:298–307.
   PubMed Web of Science ®Google Scholar
• Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015;53:e49–e57.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–590.
   PubMed Web of Science ®Google Scholar
• Goyal RK, Wheeler SB, Kohler RE, et al. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients effect of enrollment in a medical home program. N C Med J. 2014;75:231–238.
   PubMedGoogle Scholar
• Wheeler SB, Kohler RE, Goyal RK, et al. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013;51:494–502.
   PubMed Web of Science ®Google Scholar
• Ray S, Bonthapally V, McMorrow D, et al. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013;2:195–206.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Hackshaw MD, Oster G. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. J Med Econ. 2013;16:1300–1306.
   PubMedGoogle Scholar
• Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108–1117.
   PubMed Web of Science ®Google Scholar
• Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. J Natl Compr Canc Netw. 2009;7:122–192.
   PubMed Web of Science ®Google Scholar
• Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136–222.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer. Version 1 [Internet]. 2014 [cited 2018 Dec 8]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• Bonotto M, Gerratana L, Di Maio M, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast. 2017;31:114–120.
   PubMed Web of Science ®Google Scholar
• Jacobson M, Earle CC, Price M, et al. How Medicare’s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff. 2010;29:1391–1399.
   Web of Science ®Google Scholar
• Conti RM, Rosenthal MB, Polite BN, et al. Infused chemotherapy use in the elderly after patent expiration. Am J Manag Care. 2012;18:e173–e178.
   PubMed Web of Science ®Google Scholar
• Rashid N, Koh HA, Baca HC, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. J Manag Care Spec Pharm. 2015;21:863–871.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Masaquel A, Johnston S, et al. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries. J Med Econ. 2016;19:1027–1033.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014;19:901–908.
   PubMed Web of Science ®Google Scholar
• Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636–4642.
   PubMed Web of Science ®Google Scholar
• Davis KL, Iyer S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010;13:A260.
   Web of Science ®Google Scholar
• Griffiths RI, Lalla D, Herbert RJ, et al. Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest. 2011;29:573–584.
   PubMed Web of Science ®Google Scholar
• Chawla N, Yabroff R, Mariotto A, et al. Diagnosis codes for cancer metastasis on Medicare claims have limited accuracy and completeness. Clin Med Res. 2013;11:131.
   Google Scholar
• Nordstrom BL, Whyte JL, Stolar M, et al. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):21–28.
   PubMed Web of Science ®Google Scholar
• DaCosta Byfield S, Buck PO, Blauer-Peterson C, et al. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. JOP. 2016;12:159–167.
   PubMed Web of Science ®Google Scholar